Skip to content
  • Research
  • Insights
  • Testimonials
  • Blog
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • About
  • Contact Us

Debunking Subjective Methods of Key Opinion Leader Identification

  • September 1, 2010

Recent conferences and literature on effective key opinion leader engagement show that identifying and engaging thought leaders is only getting tougher. Federal and state regulations of payments made to KOLs by pharmaceutical companies (Sunshine Act) and institutional restrictions of industry-related KOL activities reinforce the importance of identifying and engaging KOLs through objective means.

Older, subjective measures for selecting KOLs, such as prescribing habits or level of influence with other physicians, leave biopharmaceutical companies open to continued scrutiny and the possibility for legal action. These methods, like social network analysis (SNA), often lack the detail that industry decision-makers need to select the right KOLs for various types of engagement. Furthermore, it is also true that some objective means of identifying and selecting KOLs have their own limitations. Tracking conference involvement and publications alone is not enough to ensure you have found the top thought leaders in a given medical specialty.

Thought Leader Select has developed a methodology that uniquely provides biopharmaceutical decision-makers with the comfort that they’re identifying and selecting KOLs for the “right reasons”. Our “deep profiling” methodology tracks KOL activities across more than a dozen different areas and provides detailed participation data in a searchable framework that enables clients to select thought leaders in more sophisticated ways. Combining “deep profiling” with Thought Leader Select’s Professional Impact Network (PIN) enables decision makers to determine a map of KOL inter-relationships based on connected interactions, such as treatment guideline development and editorial board service.

In a recent TLS Blog post, Paul Meade discusses the importance of “finding the right thought leader with the right expertise at the right time.” Companies that employ more robust, objective methods for engaging thought leaders are able to do just that – and they show a determination to work with KOLs who have demonstrated expertise, not just close relationships with other health care professionals or with industry itself. When biopharmaceutical companies seek advice and counsel from KOLs with proven track records of thought leadership, they build respect in the medical community, among patients and with the public at large.

More Posts

Haddock, Meade Tabbed to Lead New Era of TLS Research Excellence

March 30, 2021 (WASHINGTON, NC) Thought Leader Select, a North Carolina-based global leader in thought leadership research and insights for the life sciences industry, is

Focus on Micro-Influencers

By Brian Castle, Digital Insights Lead Influencers and micro-influencers both play a key role in medical innovation and communication. Let’s discuss the difficult task of

Mapping the Patient Journey

By Paul Meade, Patient Engagement Lead  Mapping the Patient Journey A vital step to improving patient engagement is defining and understanding the patient journey. While

The Importance of Patient Flow Mapping

By Paul Meade, Patient Engagement Lead  Healthcare providers and life sciences companies are increasingly looking for ways to improve patient engagement. In the past, many

Share:

Send Us A Message

  • Research
  • Insights
  • Testimonials
  • Blog
  • About
  • Contact Us
Menu
  • Research
  • Insights
  • Testimonials
  • Blog
  • About
  • Contact Us
logo-2020-300.png

1589 W. 5th Street
Washington, NC 27889
email

© 2021 All rights Reserved. THOUGHT LEADER SELECT

Facebook-f
Twitter
Linkedin